Effect of methamphetamine on the pharmacokinetics of dextromethorphan and midazolam in rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 30, Issue 3, 2005, Pages 195-201

  Dostalek, M ^a   Hadasova, E ^a   Hanesova, M ^a   Pistovcakova, J ^a   Sulcova, A ^a   Jurica, J ^a   Tomandl, J ^a   Linhart, I ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

Author keywords

CYP2D2; CYP3A1 2; Dextromethorphan; Methamphetamine; Midazolam

Indexed keywords

CANNABIS; COCAINE; CYTOCHROME P450 2D; CYTOCHROME P450 2D2; CYTOCHROME P450 3A; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; DEXTROMETHORPHAN; DEXTRORPHAN; DIAMORPHINE; DRUG METABOLITE; HYDROXYAMPHETAMINE; HYDROXYL GROUP; ISOENZYME; METHAMPHETAMINE; MIDAZOLAM; MORPHINAN DERIVATIVE; NORLEVORPHANOL; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; MALE; NONHUMAN; RAT;

EID: 27144533623     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190620     Document Type: Article

References (51)

1. Omura T, Sato R. A new cytochrome in liver microsomes. J Biol Chem 1962;237:1375-6.
2. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964; 239:2370-8.
3. Klingenberg M. Pigment of rat liver microsomes. Arch Biochem Biophys 1958;75:376-86.
4. Yan Z, Caldwell GW. Metabolism profiling, and cytochrome P450 inhibition and induction in drug discovery. Curr Top Med Chem 2001; 5:403-25.
5. Hollenberg PF. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev 2002;34:17-35.
6. Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 2001; 41:535-67.
7. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications.Clin Pharmacokinet 1998;35:361-90.
8. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119:707-13.
9. Greenway F, Herbert D, Raum W, Herber D, Morales S. Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity. Obes Res 1999; 7:370-8.
10. Anglin MD, Bruke C, Perrochet B, Stamper E, Dawud-Noursi S. History of the methamphetamine problem. J Psychoactive Drugs 2000; 32:137-41.
11. Frank RS. The clandestine drug laboratory situation in the United States. J Forens Sci 1983; 28:18-31.
12. Wijetunga M, Bhan R, Lindsay R, Krach S. Acute coronary syndrome and crystal methamphetamine use: a case series. Hawaii Med J 2004; 63:8-13.
13. Lee CY, Heffez LB, Mohammadi H. Crystal methamphetamine abuse: a concern to oral and maxillofacial surgeons. J Oral Maxillofac Surg 1992; 50:1052-4.
14. Caldwell J, Dring LG, Williems RT. Metabolism of [14C]-methamphetamine in man, the guinea pig and the rat. Biochem J 1972; 129:11-22.
15. Yamamoto T, Takano R, Egashira T, Yamanaka Y. Metabolism of methamphetamine, amphetamine and p-hydroxymethamphetamine by rat-liver microsomal preparations in vitro. Xenobiotica 1984; 14:867-75.
16. Wu D, Otton SV, Inaba T, Kallow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 1997; 53:1605-12.
17. Lin LY, Kumagai Y, Cho AK. Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy) methamphetamine by rat brain microsomes. Chem Res Toxicol 1992; 5:401-6.
18. Lin LY, Kumagai Y, Hiratsuka A, Marimatsu S, Suzuki T, Funae Y, et al. Cytochrome P4502D isozymes catalyze the 4-hydroxylation of methamphetamine enantiomers. Drug Metab Dispos 1995; 23:610-14.
19. Tucker GT, Lennard MS, ElHs SE, Woods HF, Cho AK, Lin LY, et al. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994; 47:1151-6.
20. Kobayashi K, Urashima K, Shimada N, Chiba K. Substrate specifity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed system of the rat. Biochem Pharmacol 2002; 63:889-96.
21. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 1996; 24:940-7.
22. Cotreau MM, Von Moltke LL, Beinfeld MC, Greenblatt DJ. Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level. J Pharmacol Toxicol Methods 2000; 43:41-54.
23. Nelson DR, Koymans L, Katamaki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6:1-42.
24. Nedelcheva V, Gut I. P450 in rat and man: methods of investigation, substrate specifities and relevance to cancer. Xenobiotica 1994; 24:1151-75.
25. Soucek P, Gut I. Cytochrome P450 in rats: structures, functions, properties and relevant human forms. Xenobiotika 1992; 22:83-103.
26. Walser A, Benjamin LE, Flynn T, Mason C, Chwartz R, Fryer RI. Quinazolines and 1,4-benzodiazepines. 84. Synthesis and reactions of imidazo[1,5-a] [1,4] benzodiazepines. J Org Chem 1997;43:936-44.
27. Lofgren S, Hagbjork AL, Ekman S, Frannson-Steen R, Terelius Y. Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison. Xenobiotica 2004; 34:811-34.
28. Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human microsomes: contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 48:173-82.
29. Kerry NL, Somogyi AA, Bochner F, Mikus G. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes Br J Clin Pharmacol 1994; 38:243-8.
30. Dayer P, Desmeules J, Leemann T, Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun 1998; 152:411-16.
31. Guttendorf RJ, Wedlund PJ, Blake J, Chang SL. Simplified phenotyping with dextromethorphan by thin-layer chromatography: application to clinical laboratory screening for deficiencies in oxidative drug metabolism. Ther Drug Monit 1988; 10:490-8.
32. Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M, et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 1992; 14: 8.
33. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993; 3:197-204.
34. Kerry NL, Somogyi AA, Mikus G, Bochner F. Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes. Biochem Pharmacol 1993; 45:833-9.
35. Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3 A3/4, with a possible role of 2E1. Biopharm Drug Dispos 1997; 18:227-40.
36. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992; 44:2089-98.
37. Ducharme J, Abdullah S, Wainer IW. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 1996; 678:113-28.
38. Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Wainer IW, Schwartz JB. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther 1999; 66:40-50.
39. Anzenbacher P, Anzenbacerova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001; 58:737-47.
40. Kronbach T, Mathis D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36:89-96.
41. Wandel C, Bocker R, Bohrer H, Browne A., Rugheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesthesiol 1994; 73:658-61.
42. Watanabe T, Tateishi T, Asoh M, Nakura H, Tanaka M, Kumai T, et al. Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats. Life Sci 1998; 63:1685-92.
43. Moravcik V, Zabransky T, Korsicova B, Leickova P, Skrdlanova E, Stastna L, et al. Vyroǒii zpráva ve stavu ve věcech drog v České republice v roce 2002.Úřad Vlády ČR, 2003.
44. Mattison AM, Ross MW, Wolfson T, Franclin D. Circuit party attendance, club drug use, and unsafe sex in gay men. J Subst Abuse 2001; 13:119-26.
45. Copeland AL, Sorensen JL, Differences between methamphetamine users and cocaine users in treatment. Drug Alcohol Depend 2001;62:91-5.
46. Frosch D, Shoptaw S, Huber A, Rawson RA, Ling W. Sexual HIV risk among gay and bisexual male methamphetamine abusers. J Subst Abuse Treat 1996; 13:483-6.
47. Hales G, Roth N, Smith D. Possible fatal interaction between protease inhibitors and methamphetamine. Antivir Ther 2000; 5:19.
48. Phillips TR, Billaud JN, Henriksen SJ. Methamphetamine and HIV-1: potential interactions and the use of the FIV/cat model. J Psychopharmacol 2000; 14:244-50.
49. Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care 2003; 15:775-85.
50. Semple SJ, Patterson TL, Grant I. Motivations associated with methamphetamine use among HIV+ men who have sex with men. J Subst Abuse Treat 2002; 22:149-56.
51. Zuber R, Anzenbacerova E, Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 2002; 6:189-98.